The Specimen Accessioning Core (SAC) provides a centralized resource for the collection and processing of blood, bone marrow, and tumor cell samples from patients with malignancies as well as samples from normal volunteer donors. This Core was initially established in order to facilitate and support the ongoing laboratory and clinical research within the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (SKCCC). In addition, the SAC provides rigorous quality assurance and quality control for the processing and storage of clinical samples. Thus, the specific aims of this Core are to: 1) Centralize accessioning of patient specimens, 2) Process patient specimens and tissue samples utilizing good laboratory practices (GLP) procedures, 3) Store specimens in a well-controlled and monitored environment in order to ensure sample integrity, 4) Fairly and equitably distribute accessioned samples to investigators with IRB-approved research questions. 5) Maintain a secure relational data base that includes detailed information on the handling and processing of the samples along with pertinent clinical and demographic data that correlate to the specimen. 6) Provide expertise and support to investigators in the planning of sample collection for the development of correlative biologic tests for clinical trials and for pharmacokinetic/pharmacodynamic analysis and, 7) Provide a mechanism to ensure that informed consent is provided and subjects are maximally protected when volunteering to donate tissues for ongoing and future research by maintaining an active IRB-approved clinical trial (currently RPN#00-01-27-09, Tissue and Cell Procurement Protocol) that identified the research nature of the bank and assures HIPAA-compliances. Lay: The Specimen Accessioning Core laboratory processes samples including blood, urine and bone marrow from patients treated with a variety of new anti cancer drugs in order to test the samples for the effectiveness of these new anti-cancer drugs and to determine how these drugs are metabolized by the patients. The Specimen Accessioning Core laboratory also processes and banks a variety of tumors from patients with hematologic (blood) cancers and makes the cancer cells available to investigators within the cancer center for study in the laboratory.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-51
Application #
8661013
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-05-01
Budget End
2015-04-30
Support Year
51
Fiscal Year
2014
Total Cost
$91,432
Indirect Cost
$35,107
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Gorin, Michael A; Rowe, Steven P; Patel, Hiten D et al. (2018) Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study. J Urol 199:126-132
Bharti, Santosh K; Mironchik, Yelena; Wildes, Flonne et al. (2018) Metabolic consequences of HIF silencing in a triple negative human breast cancer xenograft. Oncotarget 9:15326-15339
Jackson, Sadhana; Weingart, Jon; Nduom, Edjah K et al. (2018) The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. Fluids Barriers CNS 15:2
Dejea, Christine M; Fathi, Payam; Craig, John M et al. (2018) Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 359:592-597
Baena-Del Valle, Javier A; Zheng, Qizhi; Esopi, David M et al. (2018) MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer. J Pathol 244:11-24
Jiang, Wei; Zhou, Xiaoyan; Li, Zengxia et al. (2018) Prolyl 4-hydroxylase 2 promotes B-cell lymphoma progression via hydroxylation of Carabin. Blood 131:1325-1336
Nagai, Kozo; Hou, Lihong; Li, Li et al. (2018) Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3. Oncotarget 9:32885-32899
Sturgeon, Kathleen M; Hackley, Renata; Fornash, Anna et al. (2018) Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema. Cancer 124:95-104
Martino, Thiago; Kudrolli, Tarana A; Kumar, Binod et al. (2018) The orally active pterocarpanquinone LQB-118 exhibits cytotoxicity in prostate cancer cell and tumor models through cellular redox stress. Prostate 78:140-151
Antonarakis, Emmanuel S; Lu, Changxue; Luber, Brandon et al. (2018) Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Eur Urol 74:218-225

Showing the most recent 10 out of 2393 publications